Coloplast Lowers FY Guidance Amid Kerecis Setback

Coloplast cut FY 2025/26 organic sales growth outlook to 5‑6% and EBIT growth to ~5% due to Kerecis setbacks and weak EU wound care.
Q2 2025/26 delivered 6% organic sales and 6% currency‑adjusted EBIT growth; wound care fell 2% while vascular/respiratory rose 8% but missed forecasts.
Kerecis sales were flat with 0% EBIT margin; Coloplast recorded a DKK3 billion goodwill impairment, raising Q2 special items to about DKK3.1 billion.
Ostomy, continence and interventional urology grew 7‑8% on US men's health demand; wound dressings fell 2% after a China recall costing DKK25 million.